Cytosorbents (NASDAQ:CTSO) Stock Crosses Below Fifty Day Moving Average – Time to Sell?

Cytosorbents Corporation (NASDAQ:CTSO – Get Free Report) shares passed below its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $4.88 and traded as low as $4.78. Cytosorbents shares last traded at $4.87, with a volume of 10,996 shares.

Analyst Upgrades and Downgrades

A number of research analysts have commented on CTSO shares. Weiss Ratings restated a “sell (e+)” rating on shares of Cytosorbents in a research note on Friday, October 2nd. WBB Securities assumed coverage on shares of Cytosorbents in a research note on Wednesday, October 21st. They issued a “speculative buy” rating and a $9.50 price objective for the company. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $104.75.

View Our Latest Research Report on Cytosorbents

Cytosorbents Stock Down 9.3%

The stock has a market capitalization of $15.34 million, a price-to-earnings ratio of -0.91 and a beta of 1.49. The company has a current ratio of 0.66, a quick ratio of 0.50 and a debt-to-equity ratio of 4.70. The firm’s 50 day simple moving average is $4.88 and its 200-day simple moving average is $9.07.

Cytosorbents (NASDAQ:CTSO – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The medical research company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.32. Cytosorbents had a negative net margin of 45.06% and a negative return on equity of 689.23%. The firm had revenue of $9.73 million for the quarter, compared to analysts’ expectations of $9.90 million. Equities analysts expect that Cytosorbents Corporation will post -4.40 earnings per share for the current fiscal year.

Insider Buying and Selling at Cytosorbents

In other Cytosorbents news, CEO Phillip Chan acquired 200,000 shares of Cytosorbents stock in a transaction dated Friday, September 4th. The stock was purchased at an average cost of $0.35 per share, for a total transaction of $70,000.00. Following the completion of the acquisition, the chief executive officer directly owned 1,944,432 shares of the company’s stock, valued at $680,551.20. This represents a 11.47% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 7.80% of the company’s stock.

Cytosorbents Company Profile

(Get Free Report)

Cytosorbents Corp. develops blood-purification technologies for use in hospitals and other clinical settings. Its products are designed to work with extracorporeal circuits, where blood is circulated outside the body and passed through a purification device. The company’s best-known product, CytoSorb, is an adsorber intended to remove certain inflammatory substances and other compounds from blood. It is used in areas such as critical care and cardiac surgery. Cytosorbents also develops DrugSorb-ATR, a device designed to remove certain blood-thinning drugs during cardiac procedures.

Read More

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.